BISPECIFIC ANTIBODIES ENABLE SYNTHETIC AGONISTIC RECEPTOR T CELL THERAPY IN MELANOMA (2022) Benmebarek M, Maerkl F, Keyl J, Cadilha B, Geiger M, Karches C, Obeck H, et al. Conference contribution UNDERSTANDING HOW EPITOPE BINDING INFLUENCES ANTIBODY DEPENDENT COMPLEMENT ENGAGEMENT FOR THERAPY OF B-CELL MALIGNANCIES (2022) Bondza S, Buijs J, Lux A Conference contribution Time 2EVOLVE: predicting efficacy of engineered T-cells - how far is the bench from the bedside? (2022) Guedan S, Luu M, Ammar D, Barbao P, Bonini C, Bousso P, Buchholz CJ, et al. Journal article, Review article Time to evolve: predicting engineered T cell-associated toxicity with next-generation models (2022) Donnadieu E, Luu M, Alb M, Anliker B, Arcangeli S, Bonini C, De Angelis B, et al. Journal article, Review article Salt-inducible kinase 3 protects tumor cells from cytotoxic T-cell attack by promoting TNF-induced NF-κB activation (2022) Sorrentino A, Menevse AN, Michels T, Volpin V, Durst FC, Sax J, Xydia M, et al. Journal article Immune cell infiltration pattern in non-small cell lung cancer PDX models is a model immanent feature and correlates with a distinct molecular and phenotypic make-up (2022) Oswald E, Bug D, Grote A, Lashuk K, Bouteldja N, Lenhard D, Loehr A, et al. Journal article Inhibition of integrin αvβ6 sparks T-cell antitumor response and enhances immune checkpoint blockade therapy in colorectal cancer (2022) Busenhart P, Montalban-Arques A, Katkeviciute E, Morsy Y, Van Passen C, Hering L, Atrott K, et al. Journal article Induction chemoimmunotherapy followed by CD8+ immune cell-based patient selection for chemotherapy-free radioimmunotherapy in locally advanced head and neck cancer (2022) Hecht M, Eckstein M, Rutzner S, von der Grün J, Illmer T, Klautke G, Laban S, et al. Journal article The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL. (2022) Rejeski K, Perez A, Iacoboni G, Penack O, Bucklein V, Jentzsch L, Mougiakakos D, et al. Journal article IMMUNE PROFILING OF PATIENTS WITH ADVANCED SOLID TUMORS TREATED WITH INTRATUMORALLY ADMINISTERED CV8102 AS A SINGLE-AGENT OR IN COMBINATION WITH ANTI-PD-1 ANTIBODIES IN PHASE I CLINICAL TRIAL (2021) Codo P, Eigentler T, Heinzerling L, Krauss J, Weishaupt C, Ochsenreither S, Lebbe C, et al. Conference contribution